503b semaglutide The FDA Wins. The OFA Loses. And Is Off the Shortage List for Good Semaglutide / Niacinamide – WP

This change in body composition intensifies the risk of diabetes, cardiovascular disease, dyslipidemia (abnormal levels of lipids in the blood) and metabolic dysfunction-associated steatotic (fatty) liver disease

Gastrointestinal side effects are common and can lead to treatment discontinuation, but they can be mitigated by gradual dose up-titration

Other GLP-1 Pills in the Pipeline Although Wegovy is the first GLP-1 pill the FDA has approved for weight management, drug manufacturers are funding trials for additional oral GLP-1 medications

So, it's like for God to just even make that big of a difference to have the weigh off literally the weight, 300 lbs